Arcturus Regains KOSTAIVE Rights, Ends CSL Dispute; Cash Runway Past 2028
ARCT is trading near its 52-week low of $5.5 (11% above the low).
Summary
Arcturus reported Q2 2026 results with $191.5M in cash, down $39.4M from year-end, but now projects runway past 2028 — a significant extension. The CSL Seqirus collaboration ended via settlement: Arcturus gets a $12M payment, release from ~$16M in R&D liabilities, and full global rights to KOSTAIVE and its infectious disease vaccine portfolio. This removes a major overhang and opens partnering opportunities. Pipeline updates: ARCT-032 CF Phase 2 enrollment is progressing, with a Phase 3 decision expected Q4 2026; ARCT-810 OTC deficiency Phase 2 dosing is complete, with data and regulatory plan due this quarter. The Thermo Fisher collaboration, announced in July, provides Phase 3 manufacturing and clinical support for ARCT-032. The regained vaccine assets and extended runway strengthen the balance sheet and strategic flexibility ahead of key clinical readouts.
At the time of this announcement, ARCT was trading at $6.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $172.8M. The 52-week trading range was $5.50 to $24.17. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.